Open Journal Systems

Research progress on the relationship between testosterone and cardiovascular disease

Long Xie, Jiandi Liu, Dongming Xie

Article ID: 1887
Vol 1, Issue 1, 2020

DOI: https://doi.org/10.54517/ccr.v1i1.1887
VIEWS - 28 (Abstract)

Abstract

Testosterone is the main androgen in human body and has many important effects on cardiovascular system Testosterone deficiency is common in patients with cardiovascular diseases. Many data suggest that low serum testosterone level is related to cardiovascular diseases such as coronary heart disease, heart failure and arrhythmiahowever, the mechanism involved is not completely clearin recent years, the research on testosterone and cardiovascular diseases has attracted much attention. This paper summarizes the pathogenesis and influence of testosterone related cardiovascular diseases.

Keywords

testosterone; heart failure; coronary atherosclerotic heart disease; cardiac electrophysiology; myocardial ischemia/reperfusion

Full Text:

PDF

References

1. Brant L, Ribeiro A. Cardiovascular health: a global primordial need. Heart 2017; 104(15): 312562–312563.

2. Shores MM, Matsumoto AM. Testosterone, aging and survival: biomarker or deficiency. CurrOpin Endocrinol Diabetes Obes 2014; 21(3): 209–216.

3. Elagizi A, Khler TS, Lavie CJ. Testosterone and cardiovascular health. Mayo Clinic Proceedings 2018; 93(1): 83–100.

4. Hackett G, Kirby M. Erectile dysfunction and testosterone deficiency as cardiovascular risk factors? International Journal of Clinical Practice 2018; 72 (2): 12275–13054.

5. Morgentaler A, Zitzmann M, Traish AM, et al. Fundamental concepts regarding testosterone deficiency and treatment: International expert consensus resolutions. Journal of Urology 2016; 196(6): 1722.

6. Gururani K, Jose J, George P V. Testosterone as a marker of coronary artery disease severity in middle aged males. Indian Heart Journal, 2016, 68 Suppl 3(S3): S16.

7. Corona G, Rastrelli G, Pasquale GD, et al. Testosterone and cardiovascular risk: Meta-Analysis of interventional studies. Journal of Sexual Medicine 2018; 15 (6):820–838.

8. Griebling TL. Re: Effects of testosterone treatment in older men. Journal of Urology 2017; 197(2): 494.

9. Shores MM, Matsumoto AM. Testosterone, aging and survival: Biomarker or deficiency. Curr Opin Endocrinol Diabetes Obes 2014; 21(3): 209–216.

10. Herring MJ, Oskui PM, Hale SL, et al. Testosterone and the cardiovascular system: A comprehensive re-view of the basic science literature. J Am Heart Assoc, 2013, 2(6): e000 271.

11. Zarotsky V, Huang MY, Carman W, et al. Systematic literature review of the epidemiology of nongenetic forms of hypogonadism in adult males. Journal of Hormones 2014; 2014(1): 117.

12. Yoshihisa A, Suzuki S, Sato Y, et al. Relation of testosterone levels to mortality in men with heart failure. American Journal of Cardiology 2018; 121(11):1279–1448.

13. Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart, 2010, 96(22): 1821-1825.

14. Herring MJ, Oskui PM, Hale SL, et al. Testosterone and the cardiovascular system: A comprehensive review of the basic science literature. J Am Heart Assoc 2013; 2(6): e000271.

15. Seftel AD, Land S. Testosterone and cardiovascular disease. Lancet Diabetes & Endocrinology 2016, 67(5): 545.

16. Kloner RA, Carson C, Dobs A, et al. Testosterone and cardiovascular disease. Am Coll Cardiol 2016; 67(5): 545–557.

17. Kelly DM, Jones TH. Testosterone and cardiovascular risk in men. Frontiers of Hormone Research 2014; 43(43): 1.

18. Tambo A, Roshan MHK, Pace NP. Testosterone and cardiovascular disease. Open Cardiovascular Medi-cine Journal 2016; 10(1): 110.

19. Armstrong PW, Ezekowitz JA. Testosterone therapy in women with heart failure. Am Coll Cardiol 2010; 56(16): 1317–1319.

20. Toma M, Mcalister FA, Coglianese EE, et al. Testosterone supplementation in heart failure: a meta-analysis. Circulation Heart Failure, 2012, 5 (3): 315-321.

21. Aukrust P, Ueland T, Gullestad L, et al. Testosterone: a novel therapeutic approach in chronic heart failure? Journal of the American College of Cardiology 2009; 54(10): 928–929.

22. Kelly DM, Jones TH. Testosterone and cardiovascular risk in men. Frontiers of Hormone Research 2014; 43(43): 1.

23. Herring MJ, Oskui PM, Hale SL, et al. Testosterone and the cardiovascular system: A comprehensive review of the basic science literature. J Am Heart Assoc 2013; 2(6): e000271.

24. Morgentaler A, Miner M M, Caliber M, et al. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clinic Proceedings 2015; 90(2): 224–251.

25. Chrysant SG, Chrysant GS. Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone. Hospital Practice 2018; 46(4): 244–253.

26. Morris PD, Channer KS. Testosterone and cardiovascular disease in men. Asian Journal of Andrology 2012; 14(3): 428.

27. Seftel AD. Re: testosterone treatment and coronary artery plaque volume in older men with low testoster-one. Journal of Urology 2017; 198(4): 727.

28. Giovanni CG, Giulia R, Elisa M, et al. Testosterone replacement therapy and cardiovascular risk: A review. World Journal of Mens Health 2015; 33(3): 130–142.

29. Mathur A, Malkin C, Saeed B, et al. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. European Journal of Endo-crinology 2009; 161(3): 443–449.

30. Zhao D, Guallar E, Ouyang P, et al. Endogenous Sex Hormones and Incident Cardiovascular Disease in PostMenopausal Women. Journal of the American Col-lege of Cardiology 2018; 71(22): 2555–2566.

31. Rexrode M, Manson JAE, Lee I, et al. Sex Hormone Levels and Risk of Cardiovascular Events in Postmenopausal Women. Circulation 2003; 108 (14):1688.

32. Meun C, Franco OH, Dhana K, et al. High androgens in postmenopausal women and the risk for atherosclerosis and cardiovascular disease: The Rotterdam Study. J Clin Endocrinol Metab 2018; 103(4): 1622–1630.

33. Rosano GMC, Spoletini I, Vitale C. Cardiovascular disease in women, is it different to men? The role of sex hormones. Climacteric 2017; 20(2): 125–128.

34. Mathur A, Malkin C, Saeed B, et al. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. European Journal of Endo-crinology 2009; 161(3): 443–449.

35. Herring MJ, Oskui PM, Hale SL, et al. Testosterone and the cardiovascular system: A Comprehensive Review of the Basic Science Literature. J Am Heart Assoc 2013; 2(6): e000271.

36. Jones T H, Kelly D M. Randomized controlled trials-mechanistic studies of testosterone and the cardiovascular system. Asian Journal of Andrology, 2018 (2): 120–130.

37. Niccoli G, Milardi D, DAmario D, et al. Hypotestosteronemia is frequent in ST-elevation myocardial infarction patients and is associated with coronary microvascular obstruction. European Journal of Preventive Cardiology 2015; 22(7): 855–863.

38. Deenadayalu V, Puttabyatappa Y, Liu AT, et al. Testosterone-induced relaxation of coronary arteries: activa-tion of BKCa channels via the cGMP-dependent protein kinase. Am J Physiol Heart Circ Physiol 2012; 302 (1): H115–23.

39. Mathur A, Malkin C, Saeed B, et al. Long-term bene-fits of testosterone replacement therapy on angina threshold and atheroma in men[J]. European Journal of Endocrinology, 2009, 161(3): 443.

40. Herring MJ, Hale SL, Shi J, et al. Supraphysiological Testosterone Levels Shorten the QT Interval but do Not Alter Total Anatomic Myocardial Infarct Size in Rabbits with Acute Myocardial Infarction. plant biology, 2014, 16(3): 594–606.

41. Budoff MJ, Ellenberg SS, Lewis CE, et al. Testoster-one treatment and coronary artery plaque volume in older men with low testosterone. Jama 2017; 317 (7): 708.

42. Kelly DM, Nettleship JE, Akhtar S, et al. Testosterone suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice. Life Sciences 2014; 109(2): 95–103.

43. Kilby E, Jones H. Testosterone stimulates cholesterol efflux and metabolism in human macrophages via liver X receptor. Endocrine 2013; 109(2): 95–103.

44. Stanworth RD, Kapoor D, Channer KS, et al. Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes. Clinical Endocrinology 2011; 74 (5): 62–430.

45. Kelly DM, Sellers DJ, Woodroofe MN, et al. Effect of testosterone on inflammatory markers in the development of early atherogenesis in the testicular-feminized mouse model. Endocrine Research 2013; 38 (3): 125–138.

46. Bourghardt J, Wilhelmson AK, Alexanderson C, et al. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology 2010; 151(11): 5428–5437.

47. Baillargeon J, Urban J, Ottenbacher KJ, et al. Trends in androgen prescribing in United States. Jama Internal Medicine 2013; 173(15): 1465–6.

48. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116 (23): 2694–701.

49. Morgentaler A. Testosterone deficiency and cardiovascular mortality. Asian Journal of Andrology, 2015; 17 (1): 26 –31.

50. Araujo AB, Dixon JM, Suarez EA, et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96(10): 3007–3019.

51. Hu X, Rui L, Zhu T, et al. Low testosterone level in middle-aged male patients with coronary artery disease. European Journal of Internal Medicine, 2011, 22 (6): e133.

52. Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology 2013; 169(6): 725–33.

53. Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012; 97(6): 2050–2058.

54. Ruige J B, Mahmoud A M, Bacquer D D, et al. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011; 97(11): 870.

55. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European Journal of Endocrinology 2011; 165(5): 687–701.

56. Goodale T, Sadhu A, Petak S, et al. Testosterone and the Heart. Methodist Debakey Cardiovascular Journal 2017; 13(2): 68.

57. Zhang Y, Ouyang P, Post WS, et al. Sex-Steroid hormones and electrocardiographic qt-interval duration: findings from the third national health and nutrition examination survey and the multi-ethnic study of atherosclerosis. American Journal of Epidemiology, 2011, 174(12): 403-411.

58. Morita H, Wu J, Zipes DP. The QT syndromes: long and short. Lancet 2008; 372(9640): 750–63.

59. Charbit B, Christinmatre S, Démolis JL, et al. Effects of testosterone on ventricular repolarization in hypogonadic men. American Journal of Cardiology 2009; 103 (6): 887–90.

60. Masuda K, Takanari H, Morishima M, et al. Testosterone-mediated upregulation of delayed rectifier potassium channel in cardiomyocytes causes abbreviation of QT intervals in rats. Journal of Physiological Sciences 2018; 69(2): 335–343.

61. Lubart E, Yarovoy A, Gal G, et al. QT interval length in elderly prostatic cancer patients on anti-testosterone treatment. Israel Medical Association Journal Imaj 2015; 17(6): 356–359.

62. Noord CV, Dörr M, Sturkenboom MCJM, et al. The association of serum testosterone levels and ventricular repolarization. European Journal of Epidemiology 2010; 25(1): 21–28.

63. Kurokawa J, Furukawa T. Non-genomic action of sex steroid hormones and cardiac repolarization. Biological & Pharmaceutical Bulletin 2013; 36(1): 812.

64. Schwartz JB, Volterrani M, Caminiti G, et al. Effects of testosterone on the Q-T Interval in older men and older women with chronic heart failure. International Journal of Andrology 2011; 34(5 Pt 2): e415.